Regenicin (Regenicin) Debt-to-Asset : 0.05 (As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Debt-to-Asset?

Regenicin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.64 Mil. Regenicin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.00 Mil. Regenicin's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2023 was $11.86 Mil. Regenicin's debt to asset for the quarter that ended in Mar. 2023 was 0.05.

Regenicin Debt-to-Asset Historical Data

The historical data trend for Regenicin's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Debt-to-Asset Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Debt-to-Asset

Get a 7-Day Free Trial

6.43

91.00

144.50

120.60

42.87

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Debt-to-Asset	Get a 7-Day Free Trial															155.00	315.00	42.87	0.06	0.05

Competitive Comparison of Regenicin's Debt-to-Asset

For the Biotechnology subindustry, Regenicin's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenicin's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Regenicin's Debt-to-Asset falls into.

Regenicin Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Regenicin's Debt-to-Asset for the fiscal year that ended in Sep. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.643	+	0)	/	0.015
	=	42.87

Regenicin's Debt-to-Asset for the quarter that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.643	+	0)	/	11.859
	=	0.05

Regenicin (OTCPK:RGIN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Regenicin Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Regenicin's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines